Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Tolvaptan (Primary)
- Indications Cystinuria
- Focus Adverse reactions
- Acronyms TCUPS
- 01 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2019.
- 01 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.